Compare
SANDOSTATIN LAR DEPOT to:
Generic Name for SANDOSTATIN LAR DEPOT
Octreotide acetate 10mg, 20mg, 30mg; susp for IM inj after dilution; contains mannitol.
Legal Classification:
Rx
Pharmacological Class for SANDOSTATIN LAR DEPOT
Somatostatin analogue.
Manufacturer of SANDOSTATIN LAR DEPOT
Novartis Pharmaceuticals Corp
|
Indications for SANDOSTATIN LAR DEPOT
Long-term maintenance therapy of acromegaly in patients who have had an inadequate response or cannot be treated with surgery and/or radiotherapy and in whom immediate-release (IR) octreotide acetate is effective and tolerated.
Other Indications for SANDOSTATIN LAR DEPOT
Adult dose for SANDOSTATIN LAR DEPOT
Give by intragluteal IM inj. Not currently receiving octreotide: initiate therapy with immediate-release octreotide SC inj for at least 2 weeks. Switching from octreotide IR: initially 20mg every 4 weeks for 3months. After 3months, adjust as follows: GH≤2.5ng/mL, IGF-1 normal and clinical symptoms controlled: maintain dosage at 20mg every 4 weeks; GH≤1ng/mL, IGF-1 normal and clinical symptoms controlled: reduce to 10mg every 4 weeks; GH>2.5ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: increase to 30mg every 4 weeks; may increase to max 40mg every 4 weeks. Pituitary irradiation recipients: withdraw therapy for 8 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.
Children's dosing for SANDOSTATIN LAR DEPOT
Not recommended.
Also:
Warnings/Precautions for SANDOSTATIN LAR DEPOT
Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.
Interactions for SANDOSTATIN LAR DEPOT
Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.
Adverse Reactions for SANDOSTATIN LAR DEPOT
Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.
How is SANDOSTATIN LAR DEPOT supplied?
Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10
Multi-dose vials 200mcg/mL, 1000mcg/mL (5mL) —1
LAR kit—1 (5mL vial w. supplies)